Samsung Biologics announced that on the same day, the company's President and CEO John Rim was elected as Chair of the Board of Directors, and will further helm the company's long-term growth strategy while expanding its leadership position as a top-tier global CDMO.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
730,000 KRW | -0.27% | -2.80% | -3.95% |
May. 31 | Samsung Biologics Aims to Lower Greenhouse Gas Emissions by 2030 | MT |
May. 23 | US FDA Approves Samsung Bioepis' Eye Disease Drug Opuviz | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-3.95% | 37.57B | |
-2.29% | 89.87B | |
-13.07% | 32.75B | |
+63.05% | 26.47B | |
-22.14% | 14.25B | |
-7.96% | 12.99B | |
-9.33% | 11.93B | |
-46.33% | 10.84B | |
+5.77% | 9.11B | |
-17.66% | 7.32B |
- Stock Market
- Equities
- A207940 Stock
- News Samsung Biologics Co.,Ltd.
- Samsung Biologics Elects John Rim as Chair of the Board of Directors